Aktis Oncology, Inc. (AKTS) Revenue, Earnings & Financial Statements
$16.31NASDAQ: AKTSMarket Cap $876.61M
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Aktis Oncology, Inc. most recently reported annual revenue of $6.0M, a net loss of $64.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Aktis Oncology, Inc.: net profit was positive in 0 of 4 reported years; operating margin moved from -3500.3% to -1149.5%, a shift of +2350.8 percentage points; the most recent year shows a net loss of $64.0M.
Income Statement — 4 Years (USD millions)
Metric
2022
2023
2024
2025
Revenue
$0
$0
$1.0M
$6.0M
Operating Expenses
$20.0M
$35.0M
$54.0M
$81.0M
Operating Profit
−$20.0M
−$35.0M
−$52.0M
−$75.0M
Operating Margin
—
—
-3500.3%
-1149.5%
Other Income
$2.0M
$6.0M
$8.0M
$11.0M
Interest
$0
$0
$0
$0
Depreciation
$0
$1.0M
$2.0M
$2.0M
Profit Before Tax
−$18.0M
−$29.0M
−$44.0M
−$64.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
Net Profit
−$18.0M
−$29.0M
−$44.0M
−$64.0M
EPS
−$0.51
−$0.82
−$1.26
−$1.19
Quarterly Results — Last 8 Quarters (USD millions)
Metric
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$1.0M
$1.0M
$2.0M
$2.0M
$2.0M
$3.0M
$3.0M
$4.0M
Operating Expenses
$17.0M
$20.0M
$23.0M
$20.0M
$19.0M
$26.0M
$32.0M
$39.0M
Operating Profit
−$16.0M
−$18.0M
−$21.0M
−$18.0M
−$17.0M
−$23.0M
−$29.0M
−$35.0M
Operating Margin
-1675.8%
-1253.8%
-1309.4%
-1152.8%
-929.1%
-703.6%
-854.0%
-889.8%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$12.0M
−$15.0M
−$18.0M
−$16.0M
−$15.0M
−$18.0M
−$24.0M
−$30.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$12.0M
−$15.0M
−$18.0M
−$16.0M
−$15.0M
−$18.0M
−$24.0M
−$30.0M
EPS
−$0.23
−$0.43
−$0.34
−$0.30
−$0.28
−$0.33
−$0.44
−$0.54
Over the 4 years reported for Aktis Oncology, Inc., borrowings increased from $2.0M in 2022 to $12.0M in 2025, cash stood at $38.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 7.42 times.
Balance Sheet — 4 Years (USD millions)
Metric
2022
2023
2024
2025
Total Assets
$138.0M
$122.0M
$326.0M
$265.0M
Current Assets
$132.0M
$100.0M
$301.0M
$230.0M
Cash
$129.0M
$30.0M
$37.0M
$38.0M
Inventory
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
Fixed Assets
$5.0M
$21.0M
$21.0M
$27.0M
Capital Work in Progress
$0
$0
$0
$0
Investments
$0
$68.0M
$260.0M
$189.0M
Other Assets
$0
$0
$0
$0
Total Liabilities
$158.0M
$169.0M
$414.0M
$411.0M
Current Liabilities
$5.0M
$6.0M
$19.0M
$31.0M
Borrowings
$2.0M
$13.0M
$12.0M
$12.0M
Other Liabilities
$156.0M
$155.0M
$402.0M
$399.0M
Equity
$0
$0
$0
$0
Reserves
−$19.0M
−$46.0M
−$88.0M
−$146.0M
For Aktis Oncology, Inc., operating cash flow was positive in 1 of 4 reported years; free cash flow in the latest year was negative at $74.0M; free cash flow was positive in 1 of 4 years; financing activities used $2.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 4 Years (USD millions)
Metric
2022
2023
2024
2025
Operating Cash Flow
−$18.0M
−$30.0M
$15.0M
−$64.0M
Investing Cash Flow
−$5.0M
−$73.0M
−$193.0M
$56.0M
Financing Cash Flow
$0
$0
−$2.0M
−$2.0M
Net Cash Flow
$100.0M
−$99.0M
$8.0M
$1.0M
Free Cash Flow
−$20.0M
−$34.0M
$12.0M
−$74.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.47
EV / EBITDA
-8.59
FCF Yield
-10.79%
Quick Ratio
14.22
Interest Coverage
—
Return 1Y
—
Return 3Y
—
Return 5Y
—
Aktis Oncology, Inc. (AKTS) financials — frequently asked questions
What is Aktis Oncology, Inc.'s annual revenue?
Aktis Oncology, Inc. (AKTS) reported annual revenue of $6.0M in its most recent fiscal year.
What is Aktis Oncology, Inc.'s net profit?
Aktis Oncology, Inc. (AKTS) reported a net loss of $64.0M in its most recent fiscal year.
What is AKTS EV/EBITDA?
Aktis Oncology, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -8.59. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks